



**Merck & Co., Inc.**  
**Financial Highlights Package**  
**Fourth Quarter 2017**  
**Table of Contents**

Table 1: GAAP P&L.....	1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.....	2
Table 2a: GAAP to Non-GAAP Reconciliation 4Q17 .....	3
Table 2b: GAAP to Non-GAAP Reconciliation Dec YTD 17 .....	4
Table 2c: GAAP to Non-GAAP Reconciliation 4Q16.....	5
Table 2d: GAAP to Non-GAAP Reconciliation Dec YTD 16 .....	6
Table 3: Sales – Current Year and Prior Year by Quarter .....	7
Table 3a: Sales – U.S. / Ex- U.S. 4Q17 .....	8
Table 3b: Sales – U.S. / Ex- U.S. Dec YTD 17 .....	9
Table 3c: Sales – Pharmaceutical Geographic Split .....	10
Table 4: Other (Income) Expense .....	11
Table 5: Effects of Adoption of New Pension Accounting Standard .....	12

**CONSOLIDATED STATEMENT OF INCOME - GAAP**  
**(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)**  
**(UNAUDITED)**

Table 1

	GAAP		% Change	GAAP		% Change
	4Q17	4Q16		Full Year 2017	Full Year 2016	
Sales	\$ 10,433	\$ 10,115	3%	\$ 40,122	\$ 39,807	1%
Costs, Expenses and Other						
Materials and production <sup>(1)</sup>	3,406	3,332	2%	12,775	13,891	-8%
Marketing and administrative <sup>(1)</sup>	2,580	2,593	-1%	9,830	9,762	1%
Research and development <sup>(1)(2)</sup>	2,055	4,650	-56%	9,982	10,124	-1%
Restructuring costs <sup>(3)</sup>	306	265	15%	776	651	19%
Other (income) expense, net <sup>(1)(4)</sup>	(19)	631	*	12	720	-98%
Income (Loss) Before Taxes	2,105	(1,356)	*	6,747	4,659	45%
Income Tax Provision (Benefit) <sup>(1)</sup>	2,969	(769)		4,155	718	
Net (Loss) Income	(864)	(587)	47%	2,592	3,941	-34%
Less: Net Income Attributable to Noncontrolling Interests	8	7		24	21	
Net (Loss) Income Attributable to Merck & Co., Inc.	\$ (872)	\$ (594)	47%	\$ 2,568	\$ 3,920	-34%
(Loss) Earnings per Common Share Assuming Dilution <sup>(5)</sup>	\$ (0.32)	\$ (0.22)	45%	\$ 0.93	\$ 1.41	-34%
Average Shares Outstanding Assuming Dilution <sup>(5)</sup>	2,715	2,755		2,748	2,787	
Tax Rate <sup>(6)</sup>	141.0%	56.7%		61.6%	15.4%	

\* 100% or greater

(1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See accompanying tables for details.

(2) Research and development expenses for full year 2017 include a \$2.35 billion aggregate charge recorded in conjunction with the formation of a collaboration with AstraZeneca.

(3) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.

(4) Other (income) expense, net in the fourth quarter and full year of 2016 includes a \$625 million charge to settle worldwide patent litigation related to KEYTRUDA.

(5) Because the company recorded a net loss in the fourth quarter of 2017 and 2016, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive.

(6) The effective income tax rates for the fourth quarter and full year of 2017 reflect the net unfavorable impact of a \$2.6 billion provisional charge related to the enactment of U.S. tax legislation. The effective income tax rate for the full year of 2017 also reflects the unfavorable impact of a \$2.35 billion aggregate pretax charge recorded in conjunction with the formation of a collaboration with AstraZeneca for which no tax benefit has been recognized. Additionally, the effective income tax rate for the full year of 2017 reflects the favorable impact of a net tax benefit of \$234 million related to the settlement of certain federal income tax issues.

**MERCK & CO., INC.**  
**CONSOLIDATED STATEMENT OF INCOME - GAAP**  
**(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)**  
**(UNAUDITED)**

Table 1a

	2017					2016					% Change	
	1Q	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	4Q	Full Year	4Q	Full Year
Sales	\$ 9,434	\$ 9,930	\$ 10,325	\$ 10,433	\$ 40,122	\$ 9,312	\$ 9,844	\$ 10,536	\$ 10,115	\$ 39,807	3%	1%
Costs, Expenses and Other												
Materials and production	3,015	3,080	3,274	3,406	12,775	3,572	3,578	3,409	3,332	13,891	2%	-8%
Marketing and administrative	2,411	2,438	2,401	2,580	9,830	2,318	2,458	2,393	2,593	9,762	-1%	1%
Research and development	1,796	1,749	4,383	2,055	9,982	1,659	2,151	1,664	4,650	10,124	-56%	-1%
Restructuring costs	151	166	153	306	776	91	134	161	265	651	15%	19%
Other (income) expense, net	58	58	(86)	(19)	12	48	19	22	631	720	*	-98%
Income (Loss) Before Taxes	2,003	2,439	200	2,105	6,747	1,624	1,504	2,887	(1,356)	4,659	*	45%
Income Tax Provision (Benefit)	447	488	251	2,969	4,155	494	295	699	(769)	718		
Net Income (Loss)	1,556	1,951	(51)	(864)	2,592	1,130	1,209	2,188	(587)	3,941	47%	-34%
Less: Net Income Attributable to Noncontrolling Interests	5	5	5	8	24	5	4	4	7	21		
Net Income (Loss) Attributable to Merck & Co., Inc.	\$ 1,551	\$ 1,946	\$ (56)	\$ (872)	\$ 2,568	\$ 1,125	\$ 1,205	\$ 2,184	\$ (594)	\$ 3,920	47%	-34%
Earnings (Loss) per Common Share Assuming Dilution <sup>(1)</sup>	\$ 0.56	\$ 0.71	\$ (0.02)	\$ (0.32)	\$ 0.93	\$ 0.40	\$ 0.43	\$ 0.78	\$ (0.22)	\$ 1.41	45%	-34%
Average Shares Outstanding Assuming Dilution <sup>(1)</sup>	2,766	2,752	2,727	2,715	2,748	2,795	2,789	2,786	2,755	2,787		
Tax Rate	22.3%	20.0%	125.5%	141.0%	61.6%	30.4%	19.6%	24.2%	56.7%	15.4%		

\* 100% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

(1) Because the company recorded a net loss in the third and fourth quarter of 2017 and fourth quarter of 2016, no potential dilutive common shares were used in the computations of loss per common share assuming dilution as the effects would have been anti-dilutive.

**MERCK & CO., INC.**  
**GAAP TO NON-GAAP RECONCILIATION**  
**FOURTH QUARTER 2017**  
**(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)**  
**(UNAUDITED)**

Table 2a

	GAAP	Acquisition and Divestiture-Related Costs <sup>(1)</sup>	Restructuring Costs <sup>(2)</sup>	Certain Other Items	Adjustment Subtotal	Non-GAAP
Materials and production	\$ 3,406	737	17		754	\$ 2,652
Marketing and administrative	2,580	4	(1)		3	2,577
Research and development	2,055	(5)	-		(5)	2,060
Restructuring costs	306		306		306	-
Other (income) expense, net	(19)	1		(7)	(6)	(13)
Income Before Taxes	2,105	(737)	(322)	7	(1,052)	3,157
Income Tax Provision (Benefit)	2,969	(88) <sup>(3)</sup>	(50) <sup>(3)</sup>	2,623 <sup>(4)</sup>	2,485	484
Net (Loss) Income	(864)	(649)	(272)	(2,616)	(3,537)	2,673
Net (Loss) Income Attributable to Merck & Co., Inc.	(872)	(649)	(272)	(2,616)	(3,537)	2,665
(Loss) Earnings per Common Share Assuming Dilution	\$ (0.32)	(0.24)	(0.10)	(0.96)	(1.30)	\$ 0.98
Tax Rate	141.0%					15.3%

Only the line items that are affected by non-GAAP adjustments are shown.

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management's annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs primarily reflect expenses for the amortization of intangible assets recognized as a result of business acquisitions. Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions and divestitures. Amounts included in research and development expenses primarily reflect a reduction of expenses related to a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income) expense, net reflect goodwill and intangible asset impairment charges related to a business in the Healthcare Services segment, largely offset by royalty income in connection with the termination of the Sanofi-Pasteur MSD joint venture.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.

(4) Includes the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments, as well as a \$2.6 billion provisional charge related to the enactment of U.S. tax legislation.

**MERCK & CO., INC.**  
**GAAP TO NON-GAAP RECONCILIATION**  
**FULL YEAR 2017**  
**(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)**  
**(UNAUDITED)**

Table 2b

	GAAP	Acquisition and Divestiture-Related Costs <sup>(1)</sup>	Restructuring Costs <sup>(2)</sup>	Certain Other Items <sup>(3)</sup>	Adjustment Subtotal	Non-GAAP
Materials and production	\$ 12,775	3,187	138		3,325	\$ 9,450
Marketing and administrative	9,830	44	2		46	9,784
Research and development	9,982	284	11	2,350	2,645	7,337
Restructuring costs	776		776		776	-
Other (income) expense, net	12	19		(16)	3	9
Income Before Taxes	6,747	(3,534)	(927)	(2,334)	(6,795)	13,542
Income Tax Provision (Benefit)	4,155	(552) <sup>(4)</sup>	(182) <sup>(4)</sup>	2,304 <sup>(5)</sup>	1,570	2,585
Net Income	2,592	(2,982)	(745)	(4,638)	(8,365)	10,957
Net Income Attributable to Merck & Co., Inc.	2,568	(2,982)	(745)	(4,638)	(8,365)	10,933
Earnings per Common Share Assuming Dilution	\$ 0.93	(1.09)	(0.27)	(1.69)	(3.05)	\$ 3.98
Tax Rate	61.6%					19.1%

Only the line items that are affected by non-GAAP adjustments are shown.

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management's annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs primarily reflect \$3.1 billion of expenses for the amortization of intangible assets recognized as a result of business acquisitions, as well as \$134 million of intangible asset impairment charges. Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions and divestitures. Amounts included in research and development expenses reflect \$257 million of in-process research and development (IPR&D) impairment charges and \$27 million of expenses related to an increase in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income) expense, net reflect goodwill and intangible asset impairment charges related to a business in the Healthcare Services segment, as well as expenses related to changes in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty income in connection with the termination of the Sanofi-Pasteur MSD joint venture.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

(3) Amount included in research and development expenses represents an aggregate charge recorded in conjunction with the formation of a collaboration with AstraZeneca.

(4) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.

(5) Includes the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Also includes a \$2.6 billion provisional charge related to the enactment of U.S. tax legislation, as well as a \$234 million net tax benefit related to the settlement of certain federal income tax issues and an \$88 million tax benefit related to the settlement of a state income tax issue.

**MERCK & CO., INC.**  
**GAAP TO NON-GAAP RECONCILIATION**  
**FOURTH QUARTER 2016**  
**(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)**  
**(UNAUDITED)**

Table 2c

	GAAP	Acquisition and Divestiture-Related Costs <sup>(1)</sup>	Restructuring Costs <sup>(2)</sup>	Certain Other Items <sup>(3)</sup>	Adjustment Subtotal	Non-GAAP
Materials and production	\$ 3,332	756	32		788	\$ 2,544
Marketing and administrative	2,593	22	4		26	2,567
Research and development	4,650	2,897	9		2,906	1,744
Restructuring costs	265		265		265	-
Other (income) expense, net	631	35		564	599	32
(Loss) Income Before Taxes	(1,356)	(3,710)	(310)	(564)	(4,584)	3,228
Income Tax (Benefit) Provision	(769)	(1,303) <sup>(4)</sup>	(60) <sup>(4)</sup>	(157) <sup>(4)</sup>	(1,520)	751
Net (Loss) Income	(587)	(2,407)	(250)	(407)	(3,064)	2,477
Net (Loss) Income Attributable to Merck & Co., Inc.	(594)	(2,407)	(250)	(407)	(3,064)	2,470
(Loss) Earnings per Common Share Assuming Dilution	\$ (0.22)	(0.87)	(0.09)	(0.15)	(1.11)	\$ 0.89
Tax Rate	56.7%					23.3%

Only the line items that are affected by non-GAAP adjustments are shown.

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results and permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management's annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets recognized as a result of business acquisitions. Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions and divestitures. Amounts included in research and development expenses reflect \$3.3 billion of in-process research and development (IPR&D) impairment charges, partially offset by a reduction of expenses of \$432 million related to a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amount included in other (income) expense, net represents a goodwill impairment charge related to a business within the Healthcare Services segment.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

(3) Primarily reflects a \$625 million charge to settle worldwide patent litigation related to KEYTRUDA.

(4) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.

**MERCK & CO., INC.**  
**GAAP TO NON-GAAP RECONCILIATION**  
**FULL YEAR 2016**  
**(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)**  
**(UNAUDITED)**

Table 2d

	GAAP	Acquisition and Divestiture-Related Costs <sup>(1)</sup>	Restructuring Costs <sup>(2)</sup>	Certain Other Items <sup>(3)</sup>	Adjustment Subtotal	Non-GAAP
Materials and production	\$ 13,891	4,035	181		4,216	\$ 9,675
Marketing and administrative	9,762	78	95		173	9,589
Research and development	10,124	3,152	142		3,294	6,830
Restructuring costs	651		651		651	-
Other (income) expense, net	720	47		558	605	115
Income Before Taxes	4,659	(7,312)	(1,069)	(558)	(8,939)	13,598
Income Tax Provision (Benefit)	718	(1,936) <sup>(4)</sup>	(229) <sup>(4)</sup>	(156) <sup>(4)</sup>	(2,321)	3,039
Net Income	3,941	(5,376)	(840)	(402)	(6,618)	10,559
Net Income Attributable to Merck & Co., Inc.	3,920	(5,376)	(840)	(402)	(6,618)	10,538
Earnings per Common Share Assuming Dilution	\$ 1.41	(1.93)	(0.30)	(0.14)	(2.37)	\$ 3.78
Tax Rate	15.4%					22.3%

Only the line items that are affected by non-GAAP adjustments are shown.

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results and permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management's annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs primarily reflect \$3.7 billion of expenses for the amortization of intangible assets recognized as a result of business acquisitions, as well as \$347 million of intangible asset impairment charges. Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions and divestitures. Amounts included in research and development expenses reflect \$3.6 billion of in-process research and development (IPR&D) impairment charges, partially offset by a reduction of expenses of \$402 million related to a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income) expense, net represent goodwill impairment charges related to businesses within the Healthcare Services segment.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

(3) Primarily reflects a \$625 million charge to settle worldwide patent litigation related to KEYTRUDA.

(4) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.

**MERCK & CO., INC.**  
**FRANCHISE / KEY PRODUCT SALES**  
**(AMOUNTS IN MILLIONS)**  
**Table 3**

	2017					2016					4Q		Full Year	
	1Q	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	4Q	Full Year	Nom %	Ex-Exch %	Nom %	Ex-Exch %
<b>TOTAL SALES <sup>(1)</sup></b>	<b>\$9,434</b>	<b>\$9,930</b>	<b>\$10,325</b>	<b>\$10,433</b>	<b>\$40,122</b>	<b>\$9,312</b>	<b>\$9,844</b>	<b>\$10,536</b>	<b>\$10,115</b>	<b>\$39,807</b>	<b>3</b>	<b>2</b>	<b>1</b>	<b>1</b>
<b>PHARMACEUTICAL</b>	<b>8,185</b>	<b>8,759</b>	<b>9,156</b>	<b>9,290</b>	<b>35,390</b>	<b>8,104</b>	<b>8,700</b>	<b>9,443</b>	<b>8,904</b>	<b>35,151</b>	<b>4</b>	<b>3</b>	<b>1</b>	<b>1</b>
<b>Primary Care and Women's Health</b>														
Cardiovascular														
Zetia	334	367	320	323	1,344	612	702	671	575	2,560	-44	-45	-48	-47
Vytorin	241	182	142	186	751	277	293	273	299	1,141	-38	-41	-34	-35
Atozet	49	63	59	54	225	23	33	39	50	146	7	2	54	51
Adempas	84	67	70	79	300	33	40	48	49	169	63	60	78	77
Diabetes														
Januvia	839	948	1,012	938	3,737	906	1,064	1,006	932	3,908	1	1	-4	-4
Janumet	496	563	513	586	2,158	506	569	548	577	2,201	2	-1	-2	-3
General Medicine & Women's Health														
NuvaRing	160	199	214	188	761	175	200	195	207	777	-9	-10	-2	-3
Implanon / Nexplanon	170	178	155	183	686	134	164	148	160	606	14	13	13	13
Follistim AQ	81	79	72	66	298	94	73	101	87	355	-25	-27	-16	-16
<b>Hospital and Specialty</b>														
Hepatitis														
Zepatier	378	517	468	296	1,660	50	112	164	229	555	29	27	199	199
HIV														
Isentress / Isentress HD	305	282	310	308	1,204	340	338	372	337	1,387	-9	-11	-13	-14
Hospital Acute Care														
Bridion	148	163	185	209	704	90	113	139	139	482	50	49	46	46
Noxafil	141	155	162	179	636	145	143	147	161	595	11	8	7	7
Invanz	136	150	159	157	602	114	143	152	152	561	3	2	7	7
Candidas	121	112	94	95	422	133	131	142	152	558	-37	-39	-24	-24
Cubicin	96	103	91	92	382	292	357	320	119	1,087	-22	-23	-65	-65
Primaxin	62	71	73	74	280	73	81	77	66	297	12	10	-6	-4
Immunology														
Remicade	229	208	214	186	837	349	339	311	269	1,268	-31	-35	-34	-34
Simponi	184	199	219	217	819	188	199	193	186	766	17	10	7	6
<b>Oncology</b>														
Keytruda	584	881	1,047	1,297	3,809	249	314	356	483	1,402	169	166	172	171
Emend	133	143	137	143	556	126	143	137	144	549	-1	-2	1	1
Temodar	66	65	68	73	271	66	73	78	67	283	10	11	-4	-4
<b>Diversified Brands</b>														
Respiratory														
Singular	186	203	161	182	732	237	229	239	210	915	-13	-14	-20	-19
Nasonex	139	85	42	120	387	229	101	94	112	537	8	7	-28	-29
Dulera	82	69	59	77	287	113	121	97	105	436	-26	-27	-34	-34
Other														
Cozaar / Hyzaar	112	119	128	125	484	126	132	131	121	511	3	2	-5	-4
Aroxia	103	89	80	91	363	111	117	114	108	450	-16	-19	-19	-20
Fosamax	61	66	53	62	241	75	73	68	68	284	-9	-10	-15	-15
<b>Vaccines <sup>(2)</sup></b>														
Gardasil / Gardasil 9	532	469	675	633	2,308	378	393	860	542	2,173	17	15	6	6
ProQuad / M-M-R II / Varivax	355	399	519	403	1,676	357	383	496	405	1,640	0	-1	2	2
Pneumovax 23	163	166	229	263	821	107	120	175	238	641	11	11	28	29
RotaTeq	224	123	179	160	686	188	130	171	162	652	-1	-2	5	5
Zostavax	154	160	234	121	668	125	149	190	221	685	-45	-46	-2	-3
<b>Other Pharmaceutical <sup>(3)</sup></b>	<b>1,037</b>	<b>1,116</b>	<b>1,013</b>	<b>1,124</b>	<b>4,295</b>	<b>1,083</b>	<b>1,128</b>	<b>1,191</b>	<b>1,172</b>	<b>4,574</b>	<b>-4</b>	<b>-5</b>	<b>-6</b>	<b>-6</b>
<b>ANIMAL HEALTH</b>	<b>939</b>	<b>955</b>	<b>1,000</b>	<b>981</b>	<b>3,875</b>	<b>829</b>	<b>900</b>	<b>865</b>	<b>884</b>	<b>3,478</b>	<b>11</b>	<b>8</b>	<b>11</b>	<b>11</b>
<b>Other Revenues <sup>(4)</sup></b>	<b>310</b>	<b>216</b>	<b>169</b>	<b>162</b>	<b>857</b>	<b>379</b>	<b>244</b>	<b>228</b>	<b>327</b>	<b>1,178</b>	<b>-51</b>	<b>-27</b>	<b>-27</b>	<b>-13</b>

\* 200% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

<sup>(1)</sup> Only select products are shown.

<sup>(2)</sup> Vaccine sales in 2017 include sales in the European markets that were previously part of the Sanofi Pasteur MSD (SPMSD) joint venture that was terminated on December 31, 2016. Amounts for 2016 reflect supply sales to SPMSD.

<sup>(3)</sup> Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$88 million in the first quarter, \$87 million in the second quarter, \$89 million in the third quarter, and \$123 million in the fourth quarter of 2017 and \$103 million, \$91 million, \$135 million and \$126 million for the first, second, third and fourth quarters of 2016, respectively.

<sup>(4)</sup> Other Revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.



**MERCK & CO., INC.**  
**FRANCHISE / KEY PRODUCT SALES**  
**FOURTH QUARTER 2017**  
**(AMOUNTS IN MILLIONS)**

8

Table 3a

	Global			U.S.			International		
	4Q 2017	4Q 2016	% Change	4Q 2017	4Q 2016	% Change	4Q 2017	4Q 2016	% Change
<b>TOTAL SALES <sup>(1)</sup></b>	<b>\$10,433</b>	<b>\$10,115</b>	<b>3</b>	<b>\$4,328</b>	<b>\$4,686</b>	<b>-8</b>	<b>\$6,105</b>	<b>\$5,429</b>	<b>12</b>
<b>PHARMACEUTICAL</b>	<b>9,290</b>	<b>8,904</b>	<b>4</b>	<b>3,967</b>	<b>4,282</b>	<b>-7</b>	<b>5,323</b>	<b>4,622</b>	<b>15</b>
<b>Primary Care and Women's Health</b>									
Cardiovascular									
Zetia	323	575	-44	54	335	-84	269	240	12
Vytorin	186	299	-38	11	132	-92	176	167	5
Atozet	54	50	7		1	-97	54	49	9
Adempas	79	49	63				79	49	63
Diabetes									
Januvia	938	932	1	508	538	-6	430	394	9
Janumet	586	577	2	223	259	-14	363	318	14
General Medicine & Women's Health									
NuvaRing	188	207	-9	139	155	-10	49	52	-6
Implanon / Nexplanon	183	160	14	129	112	15	54	48	12
Follistim AQ	66	87	-25	19	36	-48	47	51	-9
<b>Hospital and Specialty</b>									
Hepatitis									
Zepatier	296	229	29	88	180	-51	208	49	*
HIV									
Isentress / Isentress HD	308	337	-9	143	175	-19	165	162	2
Hospital Acute Care									
Bridion	209	139	50	76	36	114	132	104	28
Noxafil	179	161	11	89	81	10	90	80	13
Invanz	157	152	3	93	90	4	64	63	2
Cancidas	95	152	-37	3	6	-48	92	146	-37
Cubicin	92	119	-22	40	82	-51	52	36	43
Primaxin	74	66	12	3	1	*	71	65	9
Immunology									
Simponi	217	186	17				217	186	17
Remicade	186	269	-31				186	269	-31
<b>Oncology</b>									
Keytruda	1,297	483	169	787	311	153	510	172	196
Emend	143	144	-1	85	90	-6	58	53	8
Temodar	73	67	10	12	6	101	62	61	1
<b>Diversified Brands</b>									
Respiratory									
Singulair	182	210	-13	12	11	15	170	199	-15
Nasonex	120	112	8	37	23	60	83	88	-6
Dulera	77	105	-26	70	99	-29	7	6	14
Other									
Cozaar / Hyzaar	125	121	3	3	3	18	121	118	3
Arcoxia	91	108	-16				91	108	-16
Fosamax	62	68	-9	(1)	2	-138	62	65	-4
<b>Vaccines <sup>(2)</sup></b>									
Gardasil / Gardasil 9	633	542	17	370	409	-9	262	134	96
ProQuad / M-M-R II / Varivax	403	405		316	308	2	88	97	-9
Pneumovax 23	263	238	11	189	180	5	74	57	28
RotaTeq	160	162	-1	104	126	-17	56	36	55
Zostavax	121	221	-45	66	155	-57	55	66	-17
<b>Other Pharmaceutical <sup>(3)</sup></b>	<b>1,124</b>	<b>1,172</b>	<b>-4</b>	<b>299</b>	<b>340</b>	<b>-12</b>	<b>826</b>	<b>834</b>	<b>-1</b>
<b>ANIMAL HEALTH</b>	<b>981</b>	<b>884</b>	<b>11</b>	<b>248</b>	<b>263</b>	<b>-6</b>	<b>733</b>	<b>620</b>	<b>18</b>
<b>Other Revenues <sup>(4)</sup></b>	<b>162</b>	<b>327</b>	<b>-51</b>	<b>113</b>	<b>141</b>	<b>-19</b>	<b>49</b>	<b>187</b>	<b>-74</b>

\* 200% or greater

<sup>(1)</sup> Only select products are shown.

<sup>(2)</sup> Vaccine sales in 2017 include sales in the European markets that were previously part of the Sanofi Pasteur MSD (SPMSD) joint venture that was terminated on December 31, 2016. Amounts for 2016 reflect supply sales to SPMSD.

<sup>(3)</sup> Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$123 million and \$126 million on a global basis for fourth quarter 2017 and 2016, respectively.

<sup>(4)</sup> Other Revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.

**MERCK & CO., INC.**  
**FRANCHISE / KEY PRODUCT SALES**  
**FULL YEAR 2017**  
**(AMOUNTS IN MILLIONS)**

9

Table 3b

	Global			U.S.			International		
	Full Year 2017	Full Year 2016	% Change	Full Year 2017	Full Year 2016	% Change	Full Year 2017	Full Year 2016	% Change
<b>TOTAL SALES <sup>(1)</sup></b>	<b>\$40,122</b>	<b>\$39,807</b>	<b>1</b>	<b>\$17,424</b>	<b>\$18,478</b>	<b>-6</b>	<b>\$22,698</b>	<b>\$21,329</b>	<b>6</b>
<b>PHARMACEUTICAL</b>	<b>35,390</b>	<b>35,151</b>	<b>1</b>	<b>15,854</b>	<b>17,073</b>	<b>-7</b>	<b>19,536</b>	<b>18,077</b>	<b>8</b>
<b>Primary Care and Women's Health</b>									
Cardiovascular									
Zetia	1,344	2,560	-48	352	1,588	-78	992	972	2
Vytorin	751	1,141	-34	124	473	-74	627	668	-6
Atozet	225	146	54		1	-98	225	146	55
Adempas	300	169	78				300	169	78
Diabetes									
Januvia	3,737	3,908	-4	2,153	2,286	-6	1,584	1,622	-2
Janumet	2,158	2,201	-2	863	984	-12	1,296	1,217	6
General Medicine & Women's Health									
NuvaRing	761	777	-2	564	576	-2	197	202	-2
Implanon / Nexplanon	686	606	13	496	420	18	191	186	2
Follistim AQ	298	355	-16	123	157	-22	174	197	-12
<b>Hospital and Specialty</b>									
Hepatitis									
Zepatier	1,660	555	199	771	488	58	888	67	*
HIV									
Isentress / Isentress HD	1,204	1,387	-13	565	721	-22	639	666	-4
Hospital Acute Care									
Bridion	704	482	46	239	77	*	465	405	15
Noxafil	636	595	7	309	284	9	327	312	5
Invanz	602	561	7	361	329	10	241	233	4
Cancidas	422	558	-24	20	25	-16	402	533	-25
Cubicin	382	1,087	-65	189	906	-79	193	181	7
Primaxin	280	297	-6	10	4	151	270	293	-8
Immunology									
Remicade	837	1,268	-34				837	1,268	-34
Simponi	819	766	7				819	766	7
<b>Oncology</b>									
Keytruda	3,809	1,402	172	2,309	792	192	1,500	610	146
Emend	556	549	1	342	356	-4	213	193	11
Temodar	271	283	-4	16	15	2	256	268	-4
<b>Diversified Brands</b>									
Respiratory									
Singular	732	915	-20	40	40		692	874	-21
Nasonex	387	537	-28	54	184	-71	333	352	-5
Dulera	287	436	-34	261	412	-37	26	24	9
Other									
Cozaar / Hyzaar	484	511	-5	18	16	10	466	494	-6
Arcoxia	363	450	-19				363	450	-19
Fosamax	241	284	-15	6	5	21	235	279	-16
<b>Vaccines <sup>(2)</sup></b>									
Gardasil / Gardasil 9	2,308	2,173	6	1,565	1,780	-12	743	393	89
ProQuad / M-M-R II / Varivax	1,676	1,640	2	1,374	1,362	1	303	279	9
Pneumovax 23	821	641	28	581	447	30	240	193	24
RotaTeq	686	652	5	481	482		204	169	21
Zostavax	668	685	-2	422	518	-18	246	168	47
<b>Other Pharmaceutical <sup>(3)</sup></b>	<b>4,295</b>	<b>4,574</b>	<b>-6</b>	<b>1,246</b>	<b>1,345</b>	<b>-7</b>	<b>3,049</b>	<b>3,228</b>	<b>-6</b>
<b>ANIMAL HEALTH</b>	<b>3,875</b>	<b>3,478</b>	<b>11</b>	<b>1,090</b>	<b>989</b>	<b>10</b>	<b>2,785</b>	<b>2,489</b>	<b>12</b>
<b>Other Revenues <sup>(4)</sup></b>	<b>857</b>	<b>1,178</b>	<b>-27</b>	<b>480</b>	<b>416</b>	<b>15</b>	<b>377</b>	<b>763</b>	<b>-51</b>

\* 200% or greater

<sup>(1)</sup> Only select products are shown.

<sup>(2)</sup> Vaccine sales in 2017 include sales in the European markets that were previously part of the Sanofi Pasteur MSD (SPMSD) joint venture that was terminated on December 31, 2016. Amounts for 2016 reflect supply sales to SPMSD.

<sup>(3)</sup> Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$388 million and \$455 million on a global basis for December Full Year 2017 and 2016, respectively.

<sup>(4)</sup> Other Revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.

**MERCK & CO., INC.**  
**PHARMACEUTICAL GEOGRAPHIC SALES**  
**(AMOUNTS IN MILLIONS)**  
**(UNAUDITED)**  
Table 3c

	2017					2016					% Change 4Q	% Change Full Year
	1Q	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	4Q	Full Year		
<b>TOTAL PHARMACEUTICAL</b>	<b>\$8,185</b>	<b>\$8,759</b>	<b>\$9,156</b>	<b>\$9,290</b>	<b>\$35,390</b>	<b>\$8,104</b>	<b>\$8,700</b>	<b>\$9,443</b>	<b>\$8,904</b>	<b>\$35,151</b>	<b>4</b>	<b>1</b>
<b>United States</b>	<b>3,761</b>	<b>3,929</b>	<b>4,197</b>	<b>3,967</b>	<b>15,854</b>	<b>3,913</b>	<b>4,169</b>	<b>4,710</b>	<b>4,282</b>	<b>17,073</b>	<b>-7</b>	<b>-7</b>
% Pharmaceutical Sales	45.9%	44.9%	45.8%	42.7%	44.8%	48.3%	47.9%	49.9%	48.1%	48.6%		
<b>Europe <sup>(1)</sup></b>	<b>1,977</b>	<b>2,082</b>	<b>2,174</b>	<b>2,290</b>	<b>8,522</b>	<b>1,914</b>	<b>1,997</b>	<b>1,935</b>	<b>1,843</b>	<b>7,689</b>	<b>24</b>	<b>11</b>
% Pharmaceutical Sales	24.2%	23.8%	23.7%	24.7%	24.1%	23.6%	23.0%	20.5%	20.7%	21.9%		
<b>Japan</b>	<b>688</b>	<b>818</b>	<b>756</b>	<b>780</b>	<b>3,043</b>	<b>620</b>	<b>673</b>	<b>812</b>	<b>659</b>	<b>2,764</b>	<b>18</b>	<b>10</b>
% Pharmaceutical Sales	8.4%	9.3%	8.3%	8.4%	8.6%	7.7%	7.7%	8.6%	7.4%	7.9%		
<b>Asia Pacific</b>	<b>889</b>	<b>946</b>	<b>994</b>	<b>1,054</b>	<b>3,883</b>	<b>806</b>	<b>890</b>	<b>914</b>	<b>912</b>	<b>3,522</b>	<b>16</b>	<b>10</b>
% Pharmaceutical Sales	10.9%	10.8%	10.9%	11.3%	11.0%	9.9%	10.2%	9.7%	10.2%	10.0%		
<b>China</b>	<b>328</b>	<b>353</b>	<b>377</b>	<b>439</b>	<b>1,497</b>	<b>337</b>	<b>353</b>	<b>350</b>	<b>333</b>	<b>1,374</b>	<b>32</b>	<b>9</b>
<b>Latin America</b>	<b>375</b>	<b>462</b>	<b>451</b>	<b>547</b>	<b>1,836</b>	<b>359</b>	<b>430</b>	<b>448</b>	<b>538</b>	<b>1,776</b>	<b>2</b>	<b>3</b>
% Pharmaceutical Sales	4.6%	5.3%	4.9%	5.9%	5.2%	4.4%	4.9%	4.7%	6.0%	5.1%		
<b>Eastern Europe/Middle East Africa</b>	<b>255</b>	<b>314</b>	<b>349</b>	<b>397</b>	<b>1,314</b>	<b>272</b>	<b>314</b>	<b>364</b>	<b>429</b>	<b>1,379</b>	<b>-8</b>	<b>-5</b>
% Pharmaceutical Sales	3.1%	3.6%	3.8%	4.3%	3.7%	3.4%	3.6%	3.9%	4.8%	3.9%		
<b>Canada</b>	<b>182</b>	<b>171</b>	<b>193</b>	<b>193</b>	<b>739</b>	<b>147</b>	<b>170</b>	<b>184</b>	<b>180</b>	<b>682</b>	<b>7</b>	<b>8</b>
% Pharmaceutical Sales	2.2%	2.0%	2.1%	2.1%	2.1%	1.8%	2.0%	1.9%	2.0%	1.9%		
<b>Other</b>	<b>58</b>	<b>37</b>	<b>42</b>	<b>62</b>	<b>199</b>	<b>73</b>	<b>57</b>	<b>76</b>	<b>61</b>	<b>266</b>	<b>2</b>	<b>-25</b>
% Pharmaceutical Sales	0.7%	0.4%	0.5%	0.7%	0.6%	0.9%	0.7%	0.8%	0.7%	0.8%		

<sup>(1)</sup> Europe primarily represents all European Union countries and the European Union accession markets.

**MERCK & CO., INC.**  
**OTHER (INCOME) EXPENSE, NET - GAAP**  
**(AMOUNTS IN MILLIONS)**  
**(UNAUDITED)**  
**Table 4**

**OTHER (INCOME) EXPENSE, NET**

	4Q17	4Q16	Full Year 2017	Full Year 2016
INTEREST INCOME	\$ (101)	\$ (83)	\$ (385)	\$ (328)
INTEREST EXPENSE	191	180	754	693
EXCHANGE (GAINS) LOSSES	(17)	95	(11)	174
EQUITY INCOME FROM AFFILIATES	(32)	(27)	(42)	(86)
Other, net <sup>(1)</sup>	(60)	466	(304)	267
<b>TOTAL</b>	<b>\$ (19)</b>	<b>\$ 631</b>	<b>\$ 12</b>	<b>\$ 720</b>

<sup>(1)</sup> Other, net in the fourth quarter and full year of 2016 includes a \$625 million charge to settle worldwide patent litigation related to KEYTRUDA.

**MERCK & CO., INC.**  
**EFFECTS OF ADOPTION OF NEW PENSION ACCOUNTING STANDARD**  
**(AMOUNTS IN MILLIONS)**  
**(UNAUDITED)**

**Table 5**

The 2017 financial guidance for both GAAP and non-GAAP operating expenses reflects the adoption, on January 1, 2018, of a new accounting standard related to defined benefit plans that requires the components of net benefit cost/credit (other than service costs) be presented in the statement of income outside of operating expenses. The new accounting standard requires that previously reported amounts be reclassified to conform to the new presentation. There is no impact to net income as a result of adopting the new standard. The tables below provide details of the effects of adopting the standard for the full year of 2017 and by quarter as will be presented in 2018 reporting.

	GAAP			Non-GAAP		
	As Reported 2017	Reclass	As Recast 2017	As Reported 2017	Reclass	As Recast 2017
<b>Full Year 2017</b>						
Materials and production	\$ 12,775	\$ 137	\$ 12,912	\$ 9,450	\$ 137	\$ 9,587
Marketing and administrative	9,830	244	10,074	9,784	244	10,028
Research and development	9,982	131	10,113	7,337	131	7,468
Restructuring costs	776	-	776	-	-	-
Other (income) expense, net	12	(512)	(500)	9	(512)	(503)
	<u>\$ 33,375</u>	<u>\$ -</u>	<u>\$ 33,375</u>	<u>\$ 26,580</u>	<u>\$ -</u>	<u>\$ 26,580</u>
<b>First Quarter 2017</b>						
Materials and production	\$ 3,015	\$ 34	\$ 3,049	\$ 2,097	\$ 34	\$ 2,131
Marketing and administrative	2,411	61	2,472	2,390	61	2,451
Research and development	1,796	34	1,830	1,785	34	1,819
Restructuring costs	151	-	151	-	-	-
Other (income) expense, net	58	(129)	(71)	70	(129)	(59)
	<u>\$ 7,431</u>	<u>\$ -</u>	<u>\$ 7,431</u>	<u>\$ 6,342</u>	<u>\$ -</u>	<u>\$ 6,342</u>
<b>Second Quarter 2017</b>						
Materials and production	\$ 3,080	\$ 36	\$ 3,116	\$ 2,220	\$ 36	\$ 2,256
Marketing and administrative	2,438	62	2,500	2,427	62	2,489
Research and development	1,749	33	1,782	1,733	33	1,766
Restructuring costs	166	-	166	-	-	-
Other (income) expense, net	58	(131)	(73)	19	(131)	(112)
	<u>\$ 7,491</u>	<u>\$ -</u>	<u>\$ 7,491</u>	<u>\$ 6,399</u>	<u>\$ -</u>	<u>\$ 6,399</u>
<b>Third Quarter 2017</b>						
Materials and production	\$ 3,274	\$ 33	\$ 3,307	\$ 2,481	\$ 33	\$ 2,514
Marketing and administrative	2,401	58	2,459	2,390	58	2,448
Research and development	4,383	30	4,413	1,760	30	1,790
Restructuring costs	153	-	153	-	-	-
Other (income) expense, net	(86)	(121)	(207)	(68)	(121)	(189)
	<u>\$ 10,125</u>	<u>\$ -</u>	<u>\$ 10,125</u>	<u>\$ 6,563</u>	<u>\$ -</u>	<u>\$ 6,563</u>
<b>Fourth Quarter 2017</b>						
Materials and production	\$ 3,406	\$ 34	\$ 3,440	\$ 2,652	\$ 34	\$ 2,686
Marketing and administrative	2,580	63	2,643	2,577	63	2,640
Research and development	2,055	33	2,088	2,060	33	2,093
Restructuring costs	306	-	306	-	-	-
Other (income) expense, net	(19)	(130)	(149)	(13)	(130)	(143)
	<u>\$ 8,328</u>	<u>\$ -</u>	<u>\$ 8,328</u>	<u>\$ 7,276</u>	<u>\$ -</u>	<u>\$ 7,276</u>